“The COVID mRNA SHOTS qualify as GENE THERAPY according to the EU’s definition” Eminent Canadian Bioimmunologist Jessica Rose sentenced
introduction by Fabio Giuseppe Carlo Carisio
We have published multiple scientific articles regarding the classification of the so-called COVID-19 vaccines as gene therapies.
In particular, we recall the pronouncement to this effect by the Health Commissioner for the COVID emergency appointed by the Government of Slovakia, Dr. Peter Kotlar, and the study by independent French researcher Helene Banoun of Marseille published in the International Journal of Molecular Sciences on June 9, 2023.
Now here is a detailed scientific article published on her Substack by renowned Canadian bioimmunologist Jessica Rose, confirming the identification of COVID-19 mRNA gene sera as gene therapies based on official European Union documentation.
The Bioimmunologist Jessica Rose Conclusions: “COVID-19 mRNA shots are Gene Therapies”
Before republishing the entire text of the researcher who made multiple discoveries on the serious genetic consequences of Covid vaccines, we report the final conclusions as they are the least technical and most understandable even for non-experts.
«According to the Annex (of the EU documentation – ed.), gene therapy is a medicinal product obtained by manufacturing processes that transfer a prophylactic, diagnostic or therapeutic gene (nucleic acid) into human or animal cells (either in vivo or ex vivo) via a viral or non-viral vector (or genetically modified cells) for its subsequent in vivo expression» the expert scientist highlighted in her conclusion.
«If we replace the words “into human or animal cells (either in vivo or ex vivo)” with “into a human being”, and define a non-viral vector as an LNP, then does this definition of gene therapy apply to the nucleoside-modified mRNA-LNP COVID-19 injectable products since they were designed to deliver nucleic acids (mRNA) to cells via LNPs? The answer is YES» sentenced the bioimmunoligist Rose.
«The official regulatory classification loopholes this, however, because regulators carve out “infectious disease vaccines” from gene therapy rules, regardless of the delivery technology (LNP) or nucleic acid nature. This distinction, however, is based on semantics and policy, rather than underlying biological mechanisms. But here’s the thing about that: the human immune system does not respond to policy; it does, however, respond to foreign DNA and RNA introduced directly into cells via LNPs» she added.
The danger of lipid nanoparticles for DNA and the entire genetic-immune system has recently been confirmed by the latest peer-reviewed study by Italian biochemist Gabriele Segalla.
The COVID mRNA shots qualify as gene therapy according to the EU’s definition
by Jessica Rose – originally published on her Substack Unaccettable Jessica
Jessica Rose has BSc. in Applied Mathematics, an MSc. in Immunology, a PhD in Computational Biology and a two Post Docs in Molecular Biology and Biochemistry.
All links to previous Gospa News posts and videos have been added in the aftermath by virtue of the ties with covered topics
A commenter on my previous article brought a website to my attention that defines gene therapy. The website is here, and the definition is as follows as per PART IV – ADVANCED THERAPY MEDICINAL PRODUCTS:
GENE THERAPY MEDICINAL PRODUCTS (HUMAN AND XENOGENEIC)
For the purposes of this Annex, gene therapy medicinal product shall mean a product obtained through a set of manufacturing processes aimed at the transfer, to be performed either in vivo or ex vivo, of a prophylactic, diagnostic or therapeutic gene (i.e. a piece of nucleic acid), to human/animal cells and its subsequent expression in vivo. The gene transfer involves an expression system contained in a delivery system known as a vector, which can be of viral, as well as non-viral origin. The vector can also be included in a human or animal cell.
Diversity of gene therapy medicinal products
1.1. Diversity of gene therapy medicinal products
a) Gene therapy medicinal products based on allogeneic or xenogeneic cells
The vector is ready-prepared and stored before its transfer into the host cells.
The cells have been obtained previously and may be processed as a cell bank (bank collection or bank established from procurement of primary cells) with a limited viability.
The cells genetically modified by the vector represent an active substance.
Additional steps may be carried out in order to obtain the finished product. By essence, such a medicinal product is intended to be administered to a certain number of patients.
b) Gene therapy medicinal products using autologous human cells
The active substance is a batch of ready-prepared vector stored before its transfer into the autologous cells.
Additional steps may be carried out in order to obtain the finished medicinal product.
Those products are prepared from cells obtained from an individual patient. The cells are then genetically modified using a ready-prepared vector containing the appropriate gene that has been prepared in advance and that constitutes the active substance. The preparation is re-injected into the patient and is by definition intended to a single patient. The whole manufacturing process from the collection of the cells from the patient up to the re-injection to the patient shall be considered as one intervention.
c) Administration of ready-prepared vectors with inserted (prophylactic, diagnostic or therapeutic) genetic material
The active substance is a batch of ready-prepared vector.
Additional steps may be carried out in order to obtain the finished medicinal product. This type of medicinal product is intended to be administered to several patients.
Transfer of genetic material may be carried out by direct injection of the ready-prepared vector to the recipients.
Specific requirements regarding Module 3
1.2. Specific requirements regarding Module 3
Gene therapy medicinal products include:
– naked nucleic acid
– complex nucleic acid or non viral vectors
– viral vectors
– genetically modified cells
As for other medicinal products, one can identify the three main elements of the manufacturing process, i.e.:
– starting materials: materials from which the active substance is manufactured such as, gene of interest, expression plasmids, cell banks and virus stocks or non viral vector;
– active substance: recombinant vector, virus, naked or complex plasmids, virus producing cells, in vitro genetically modified cells;
– finished medicinal product: active substance formulated in its final immediate container for the intended medical use. Depending on the type of gene therapy medicinal product, the route of administration and conditions of use may necessitate an ex vivo treatment of the cells of the patient (see 1.1.b).
A special attention shall be paid to the following items
A special attention shall be paid to the following items:
a) Information shall be provided on the relevant characteristics of the gene therapy medicinal product including its expression in the target cell population. Information concerning the source, construction, characterisation and verification of the encoding gene sequence including its integrity and stability shall be provided. Apart from therapeutic gene, the complete sequence of other genes, regulatory elements and the vector backbone shall be provided.
b) Information concerning the characterisation of the vector used to transfer and deliver the gene shall be provided. This must include its physico-chemical characterisation and/or biological/immunological characterisation.
For medicinal products that utilise a micro-organism such as bacteria or viruses to facilitate gene transfer (biological gene transfer), data on the pathogenesis of the parental strain and on its tropism for specific tissues and cell types as well as the cell cycle-dependence of the interaction shall be provided.
For medicinal products that utilise non-biological means to facilitate gene transfer, the physico-chemical properties of the constituents individually and in combination shall be provided.
c) The principles for cell banking or seed lot establishment and characterisation shall apply to gene transfer medicinal products as appropriate.
d) The source of the cells hosting the recombinant vector shall be provided.
The characteristics of the human source such as age, sex, results of microbiological and viral testing, exclusion criteria and country of origin shall be documented.
For cells of animal origin, detailed information
For cells of animal origin, detailed information related to the following items shall be provided:
– Sourcing of the animals
– Animal husbandry and care
– Transgenic animals (methods of creation, characterisation of transgenic cells, nature of the inserted gene)
– Measures to prevent and monitor infections in the source/donor animals
– Testing for infectious agents
– Facilities
– Control of starting and raw materials.
Description of cell collection methodology including location, type of tissue, operating process, transportation, storage and traceability as well as controls carried out during the collection process shall be documented.
e) The evaluation of the viral safety as well as the traceability of the products from the donor to the finished medicinal product, are an essential part of the documentation to be supplied. E.g., the presence of replication competent virus in stocks of non-replication competent viral vectors must be excluded.
Succinct summary
According to the Annex, gene therapy is a medicinal product obtained by manufacturing processes that transfer a prophylactic, diagnostic or therapeutic gene (nucleic acid) into human or animal cells (either in vivo or ex vivo) via a viral or non-viral vector (or genetically modified cells) for its subsequent in vivo expression.
If we replace the words “into human or animal cells (either in vivo or ex vivo)” with “into a human being”, and define a non-viral vector as an LNP, then does this definition of gene therapy apply to the nucleoside-modified mRNA-LNP COVID-19 injectable products since they were designed to deliver nucleic acids (mRNA) to cells via LNPs?
mRNA-LNP COVID-19 injectable products are Gene Therapy? The answer is YES.
The official regulatory classification loopholes this, however, because regulators carve out “infectious disease vaccines” from gene therapy rules, regardless of the delivery technology (LNP) or nucleic acid nature. This distinction, however, is based on semantics and policy, rather than underlying biological mechanisms.
But here’s the thing about that: the human immune system does not respond to policy; it does, however, respond to foreign DNA and RNA introduced directly into cells via LNPs.
I asked Grok to make me a beautiful, yet ugly depiction of gene therapy and it generated the following image.
What’s with the eyeballs! I didn’t prompt that!
by Jessica Rose – originally published on her Substack Unaccettable Jessica
Jessica Rose has BSc. in Applied Mathematics, an MSc. in Immunology, a PhD in Computational Biology and a two Post Docs in Molecular Biology and Biochemistry.
RELATED POST
